FDA Announces Collection of Information for Review Under Paperwork Reduction Act

Summary

The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance, as required by the Paperwork Reduction Act of 1995, in order to inform industry on formal meetings between the FDA and biosimilar biological product sponsors or applicants.